Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025

Dyne Therapeutics, Inc.

Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).
Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.
Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.
Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.
Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dyne Therapeutics, Inc. reported the fourth quarter and full year 2023 results: net income Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share, EPS $1.09 per basic and diluted share.

Period: the fourth quarter and full year 2023
Net income: Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share
EPS: $1.09 per basic and diluted share
Result: reported results

Exact text from the filing

Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-025408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.